Evidence map›Paper›PMID 35450499›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Design, synthesis, and cytotoxic activities of isaindigotone derivatives as potential anti-gastric cancer agents.

Kangjia Du, Wantong Ma, Chengjie Yang, Zhongkun Zhou, Shujian Hu, Yanan Tian, Hao Zhang, Yunhao Ma, Xinrong Jiang, Hongmei Zhu and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kangjia DuSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Wantong MaSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Chengjie YangSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Zhongkun ZhouSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Shujian HuSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Yanan TianSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Hao ZhangSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Yunhao MaSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Xinrong JiangSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Hongmei ZhuSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Huanxiang LiuSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Peng ChenSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Yingqian LiuSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel derivatives of isaindigotone, which comes from the root of

Indexed as

Antineoplastic AgentsStomach NeoplasmsAlkaloidsApoptosisCell Line, TumorCell ProliferationHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuinazolinesTOR Serine-Threonine KinasesAlkaloidsAntineoplastic AgentsisaindigotonePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuinazolinesTOR Serine-Threonine KinasesapoptosiscytotoxicityIsaindigotoneMMPPI3K/AKT/mTOR

Identifiers

PMID35450499
PMCPMC9037217
OpenAlexW4224231219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.